The story so far: In early February, the Ministry of Health pulled up at least twenty companies including Tata-1mg, Flipkart, Apollo, PharmEasy, Amazon and Reliance Netmeds, by issuing them a show cause notice, for selling medicines online. This happened after the All India Organisation of Chemists and Druggists (AIOCD), a powerful lobby of over 12 lakh pharmacists, threatened to launch a country-wide agitation if the government didn’t act. Health Minister Dr. Mansukh Mandaviya in close door meetings with senior officials of the Ministry has made clear the pitfalls of selling medicines virtually. The Minister went so far as to say that e-pharmacies should be closed down.
Is banning e-pharmacies a viable option?
The Ministry of Health has adopted a ‘blow hot blow cold’ approach towards online pharmacies. The acute need for door step delivery of drugs was felt during COVID-19. The year of 2020 marked a watershed moment for the growth of e-pharmacies as the Ministry of Home Affairs issued orders for them to continue to operate. It saw nearly 8.8 million households using home delivery services during lockdown.
A senior official from the Health Ministry told The Hindu, “Banning e-pharmacies would be like throwing the baby out with the bath water. The demand for online delivery of drugs is burgeoning. There is a possibility that some of these businesses will go underground if banned, because people are not going to stop ordering medicines online anytime soon.” One can’t wish away the sale of drugs online by threatening to ban businesses, instead of regulating the sector, the official added.
The draft e-pharmacy rules, which were originally intended to whip e-pharmacy businesses into shape were floated by the Ministry of Health in 2018. The rules were finalised, public comments were taken into consideration and they were almost on the brink of being notified. But the proposal was abruptly shoved into cold storage, after being referred to a Group of Ministers including Amit Shah (home) and Rajnath Singh (defence) as the matter was considered ‘sensitive,’. It ran the risk of irking a substantial vote bank of offline pharmacists.
Since then, multiple court orders including those from Bombay, Madras, Delhi and Patna High Court have called for regulating e-pharmacies. The latest in the line is the 172nd Parliamentary Standing Committee report released in June last year, which found it ‘appalling,’ that e-pharmacy rules had not been notified even after four years of the draft being introduced.
How are e-pharmacies competing with mom-and-pop chemist shops?
Flush with billions of dollars of private equity money to infuse, e-pharmacies made a bang in the market in 2015 and started offering hefty discounts on medicines in a bid to garner more market share. But they didn’t just stop at the discounts.
E-pharmacies call themselves facilitators of doorstep delivery. They claim tie-ups with retail chemists for vending medicines. However, since profit margins in the drug retail industry are very thin, just about 15% to 16%, every player in the supply chain is struggling to make money. Therefore, companies like PharmEasy, in a move to circumvent retail chemists are building a supply chain from the ground up by buying out big and small wholesale drug distributors like Ascent Health, Desai Pharma, Eastern Agencies Healthcare among others.
Reliance bought out a Bengaluru-based software company C-Square Info Solutions, which caters to the software needs of local pharmacists since the past twenty years. But this aggressive growth is coming at a cost. It is to be noted that since 2015, e-pharmacies have recorded losses year-on-year. Tata-1 Mg posted a loss of ₹146 crore in FY22, whereas PharmEasy’s losses widened to ₹2,700 crore in the same fiscal.
What next?
Both e-pharmacies and offline retail pharmacists have realised that in a climate where drug delivery is driven by consumer sentiments, it is futile to stick to any one way of doing business. “In the past eight years, the market penetration of e-pharmacies has seen single digit growth from 3% to 5%. It is just one additional option for consumers for buying chronic care medicines for diabetes, high blood pressure, cardiac issues and so on,” said a leading e-pharmacy player who did not wish to be quoted.
For acute care and emergency, patients still rely on their neighbourhood pharmacy stores.
This has led e-pharmacy players to now open capital-intensive brick and mortar stores. Until March 2021, Reliance had opened 114 pharmacies inside their Smartpoint grocery stores. It plans to open 2,000 more outlets. Apollo Pharmacy which has more than 4,000 physical stores also caters to online sales. “PharmEasy has close to 600 of its own stores while Tata-1Mg has over fifty stores and is adding more,” the aforementioned player said.
Stiff competition has forced mom and pop pharmacists to also offer home delivery options to their customers by introducing their own store apps. They even give customers options to order medicines over Whatsapp. In an eco-system that is moving towards a hybrid mode, all eyes are on the Ministry of Health which will have to effectively regulate the new way of doing e-commerce in the drug space.
- The Ministry of Health in early February pulled up at least twenty companies including Tata-1mg, Flipkart, Apollo, PharmEasy, Amazon and Reliance Netmeds, by issuing them a show cause notice, for selling medicines online.
- This happened after the All India Organisation of Chemists and Druggists (AIOCD), a powerful lobby of over 12 lakh pharmacists, threatened to launch a country-wide agitation if the government didn’t act.
- In an eco-system that is moving towards a hybrid mode, all eyes are on the Ministry of Health which will have to effectively regulate the new way of doing e-commerce in the drug space.
Published - February 28, 2023 11:17 pm IST
